AG-270

CAS No. 2201056-66-6

AG-270( —— )

Catalog No. M28586 CAS No. 2201056-66-6

AG-270 is an allosteric and orally active inhibitor of MAT2A.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 155 In Stock
5MG 257 In Stock
10MG 377 In Stock
25MG 629 In Stock
50MG 863 In Stock
100MG 1200 In Stock
200MG 1637 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AG-270
  • Note
    Research use only, not for human use.
  • Brief Description
    AG-270 is an allosteric and orally active inhibitor of MAT2A.
  • Description
    AG-270 is an allosteric and orally active inhibitor of MAT2A.(In Vitro):AG-270 exhibits an IC50 of 20 nM in HCT116 MTAP-null cell SAM at 72 h.AG-270 demonstrates potent reduction in levels of intracellular SAM, as well as MTAP-null–selective antiproliferative activity in the HCT116 MTAP isogenic cell model in vitro.
  • In Vitro
    AG-270 demonstrates potent reduction in levels of intracellular SAM, as well as MTAP-null–selective antiproliferative activity in the HCT116 MTAP isogenic cell model in vitro.AG-270 exhibits an IC50 of 20 nM in HCT116 MTAP-null cell SAM at 72 h.MAT2A is a key enzyme in the methionine salvage pathway, responsible for generating the universal methyl donor, S-adenosylmethionine (SAM).
  • In Vivo
    AG-270 shows excellent microsomal, hepatocyte, and in vivo metabolic stability across species (human, mouse, rat, dog, and monkey). AG-270 exhibits T1/2 values of 5.9 h, 4.2 h, 4.8 h and 21.3 h in mouse, rat, monkey and dog, respectively.AG-270 (200 mg/kg, orally, q.d. for 38 days) results in dose-dependent reduction in tumor SAM levels and tumor growth of KP4 MTAP-null xenografts and is well tolerated, with mean body weight loss <5%.Combining AG-270 with taxanes and gemcitabine yielded additive-tosynergistic antitumor activity, with the docetaxel combination yielding 50% complete tumor regressions in select models; combination benefits are observed in PDX models derived from esophageal, NSCLC, and pancreatic cancers. Animal Model:Pancreatic KP4 MTAP-null xenograft mouse model.Dosage:10-200 mg/kg.Administration:Orally, q.d. for 38 days.Result:Led to dose-dependent reductions in tumor SAM levels and tumor growth of KP4 MTAP-null xenografts (TGI = 36% (10 mg/kg), 48% (30 mg/kg), 66% (100 mg/kg), 67% (200 mg/kg).
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2201056-66-6
  • Formula Weight
    489.57
  • Molecular Formula
    C30H27N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 4 mg/mL (8.17 mM)
  • SMILES
    COc(cc1)ccc1C(C(n1nc2-c3ccccc3)=O)=C(Nc3ncccc3)Nc1c2C1=CCCCC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bagalagel, Alaa A.; Bogari, Hanin A.; Ahmed, Safwat A.; Diri, Reem M.; Elhady, Sameh S.[Heterocycles, 2018, vol. 96, # 4, p. 749 - 756]
molnova catalog
related products
  • ZINC77292789

    Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a reagent for the preparation of a synthetic MUC1 Glycopeptide Bearing βGalNAc-?Thr as a Tn antigen isomer which induces the antibody production against tumor cells. Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a starting material to make trimeric MUC1 immunodominant motif antigen-?based anti-?cancer vaccine candidates.

  • 2-Deoxy-D-galactose

    2-Deoxy-D-galactose is a glucose analog and glucose antagonist that inhibits the maintenance of hippocampal LTP and can suppress tumor growth by inhibiting the glycolytic process.

  • (D-Phe2·6,Pro3)-LHRH

    (D-Phe2·6,Pro3)-LHRH